Clinical Trials at Cancer Care Associates of York
As of August 2026, 31 paid clinical trials are recruiting at Cancer Care Associates of York, located at 25 MONUMENT RD, SUITE 294, YORK, PA 17403-5060, phone (717) 741-9229 in York, Pennsylvania. Active studies at this site cover conditions such as Stage IV Lung Cancer AJCC v8, Coronary Artery Disease and Anatomic Stage II Breast Cancer AJCC v8. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
31 clinical trials at Cancer Care Associates of York
·Clear filters·A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
GEMINI-NSCLC: NSCLC Biomarker Study
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Prospective Study to Assess a Diagnostic Aid for Cancer
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
CtDNA Based MRD Testing for NAC Monitoring in TNBC
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Common conditions studied in York
- Stage IV Lung Cancer AJCC v8 (6 active studies)
- Coronary Artery Disease (5 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (4 active studies)
- Breast Cancer (4 active studies)
- Head and Neck Squamous Cell Carcinoma (4 active studies)
- Non-Small Cell Lung Cancer (4 active studies)
Leading research sponsors in York
- NRG Oncology
- SWOG Cancer Research Network
- AstraZeneca
- Tempus AI
- WellSpan Health
Frequently asked questions
How many paid clinical trials are currently recruiting in York?
There are approximately 94 recruiting clinical trials in York, Pennsylvania listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in York pay participants?
Most recruiting trials in York compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in York?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in York?
The most common conditions under active study in York include Stage IV Lung Cancer AJCC v8 (6), Coronary Artery Disease (5), Anatomic Stage II Breast Cancer AJCC v8 (4), Breast Cancer (4), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in York?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in York on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in York?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in York?
Recruiting research sites in York include Cancer Care Associates of York, WellSpan Health-York Cancer Center, WellSpan Health-York Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in York right now?
The largest active categories in York are Cancer & tumors (63), Cardiovascular (13), Neurology & pain (2). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Cancer Care Associates of York?
Cancer Care Associates of York is located at 25 MONUMENT RD, SUITE 294, YORK, PA 17403-5060. Use the Google Maps link in the intro above to get directions.
How do I contact Cancer Care Associates of York?
You can reach Cancer Care Associates of York by phone at (717) 741-9229. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.